NOS2 and Parkinson disease: [137] In rats afflicted with PD induced by LPS, farrerol mitigates the microglial activation by suppressing the level of Iba-1 via downregulating the expression of the MAPK/AKT/NF-κB pathway, decreasing the expression of TNF-α, IL-1β, IL-6, and iNOS, thus preventing the loss of dopaminergic neurons and easing motor dysfunction in PD rats.[138]